Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM0Z7PK)

• Drug Name: UC-38 Drug Info
• Synonyms: NSC-629243; NSC-D-629243

Indication

Disease Entry	ICD 11	Status	REF
Human immunodeficiency virus infection	1C62	Terminated	[1]

• Cross-matching ID:
  PubChem CID: 3000477
  CAS Number: CAS 135812-34-9
  TTD Drug ID: DM0Z7PK

Molecule-Related Drug Atlas

Drug(s) Targeting Human immunodeficiency virus Reverse transcriptase (HIV RT)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zidovudine	DM4KI7O	Human immunodeficiency virus infection	1C62	Approved	[3]
Nevirapine	DM6HX9B	Human immunodeficiency virus infection	1C62	Approved	[4]
Zalcitabine	DMH7MUV	Human immunodeficiency virus infection	1C62	Approved	[5]
Tenofovir	DM1IS6U	Chronic hepatitis B virus infection		Approved	[3]
Lamivudine	DMI347A	Chronic HBV infection	1E51.0Z	Approved	[6]
Abacavir	DMMN36E	Human immunodeficiency virus infection	1C62	Approved	[7]
Delavirdine	DM3NF5G	Human immunodeficiency virus infection	1C62	Approved	[6]
Efavirenz	DMC0GSJ	Human immunodeficiency virus infection	1C62	Approved	[6]
Rilpivirine	DMJ0QOW	Human immunodeficiency virus infection	1C62	Approved	[8]
Etravirine	DMGV8QU	Human immunodeficiency virus-1 infection	1C62	Approved	[9]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Human immunodeficiency virus Reverse transcriptase (HIV RT)	TT84ETX	POL_HV1B1	Modulator	[2]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800005073)
• [2] Biological and biochemical anti-human immunodeficiency virus activity of UC 38, a new non-nucleoside reverse transcriptase inhibitor. J Pharmacol Exp Ther. 1996 Jan;276(1):298-305.
• [3] Antiviral drugs in current clinical use. J Clin Virol. 2004 Jun;30(2):115-33.
• [4] HIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanism.Nat Struct Mol Biol.2012 Jan 22;19(2):253-9.
• [5] A peptide inhibitor of HIV-1 reverse transcriptase using alpha,beta-dehydro residues: a structure-based computer model. J Biomol Struct Dyn. 1998 Oct;16(2):347-54.
• [6] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [7] Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only Curr HIV Res. 2009 May;7(3):320-6.
• [8] Emerging antiviral drugs. Expert Opin Emerg Drugs. 2008 Sep;13(3):393-416.
• [9] 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.